Canada markets closed

Heat Biologics, Inc. (HTBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1900+0.0200 (+1.71%)
At close: 4:00PM EDT

1.1500 -0.04 (-3.36%)
After hours: 4:01PM EDT

Heat Biologics, Inc.

627 Davis Drive
Suite 400
Morrisville, NC 27560
United States
919 240 7133
http://www.heatbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Alan WolfFounder, Chairman, CEO & Pres808.23kN/A1963
Mr. William L. OstranderVP of Fin., Controller & Sec.230.62kN/A1968
Dr. Jeff T. HutchinsChief Scientific Officer & COO446.39kN/A1959
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Colonel George E. Peoples Jr., F.A.C.S., M.D., FACSChief Medical AdvisorN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Corporate Governance

Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.